The results of
an advanced clinical trial suggest that prostate cancer could be
treated with single dose radiotherapy, rather than life-altering hormone
therapy.
“Ultimately our hope is to delay lifelong hormone therapy, and its
potential side-effects, with a once-off (radiotherapy) treatment,” trial leader, Shankar Siva, said.
“This would represent a major quality-of-life improvement for these
men, and a real advance in the way we treat prostate cancer.”
Participants in the study would normally have been put on lifelong,
testosterone-blocking hormone therapy, the side effects of which include
menopause-like symptoms, such as hot flushes, loss of libido and
longer-term bone issues like osteoporosis.
Over two years, 33 trial patients were given the new method of treatment and monitored.
After which, “about half of the patients in the trial didn’t need
hormone therapy and in about a third, the cancer didn’t come back during
the study period at all,” Siva said.
The research, conducted by the Peter MacCallum Cancer Centre in the
Australian State of Victoria, found that overall 93 per cent of the
treated cancer spots were controlled with the radiation treatment.
In a day visit requiring only about an hour, the technique known as
Stereotactic Ablative Body Radiotherapy (SABR), delivers a pinpoint
accurate dose of radiotherapy to tumour sites.
“It’s just a simple outpatient day visit for about an hour to have each SABR treatment and that’s it,” Siva said.
Following the treatment, the patient’s quality of life was assessed
using questionnaires and found to be maintained at pretreatment levels.
No comments:
Post a Comment
Disclaimer: Comment expressed do not reflect the opinion of African Parliamentary News